Sanofi Press Releases

SNY 
$52.03
*  
0.08
0.15%
Get SNY Alerts
*Delayed - data as of Jul. 24, 2014  -  Find a broker to begin trading SNY now
Exchange: NYSE
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save stocks for next time
Viewing
Filtered By
Ordered By

Sanofi Pasteur Begins Shipping Seasonal Influenza Vaccine for Upcoming 2014-2015 Season in United States
7/22/2014 8:45:00 AM - PR Newswire

Regeneron and Sanofi Announce Positive Results from Phase 2b Study of Dupilumab in Patients with Moderate-to-Severe Atopic Dermatitis
7/9/2014 5:00:00 PM - PR Newswire

FDA Accepts Sanofi's New Drug Application for Basal Insulin Toujeo®
7/8/2014 8:01:00 AM - PR Newswire

CureVac Signs an Exclusive License Agreement with Sanofi Pasteur to Develop and Commercialize an mRNA-based Prophylactic Vaccine
7/1/2014 9:00:00 AM - PR Newswire

Genzyme’s Lemtrada Approved in Argentina for Treatment of Multiple Sclerosis
6/30/2014 8:00:00 AM - Business Wire

Sanofi Reports Positive Phase 3 Results for Toujeo(R)
6/14/2014 1:09:00 PM - GlobeNewswire

Sanofi's Lyxumia® (lixisenatide) Showed More Pronounced After-Test-Meal Blood Sugar Lowering than Liraglutide when Both were Added to Insulin Glargine
6/14/2014 1:02:00 PM - PR Newswire

Sanofi Reports Positive Phase 3 Results for Toujeo® (insulin glargine [rDNA origin] injection, 300 U/mL)
6/14/2014 1:02:00 PM - PR Newswire

Patients Continuing On Sanofi's Lantus® Had Lower Blood Sugar Levels Than Those who Switched to Insulin Detemir
6/14/2014 1:02:00 PM - PR Newswire

Sanofi and Medtronic to Form Strategic Alliance in Diabetes to Improve Patient Experience and Outcomes
6/14/2014 10:12:00 AM - GlobeNewswire

Society for Clinical Research Sites' Global Impact Partner Program Experiences Rapid Growth, Welcomes Four New Members
6/13/2014 9:19:00 AM - PR Newswire

Sanofi and Regeneron Announce New, Detailed Data from Positive Sarilumab Phase 3 Rheumatoid Arthritis Trial at EULAR
6/12/2014 1:00:00 AM - PR Newswire

Global Pressure Mounts to Revoke Russia’s Hosting of FIFA’s 2018 World Cup
6/5/2014 12:32:00 PM - Business Wire

Pharma Stocks under Review -- Research on Mylan, Sanofi, Impax Laboratories, and Dr. Reddy's Laboratories
6/3/2014 7:30:00 AM - PR Newswire

Genzyme’s Lemtrada Resubmission Accepted for Review by FDA
5/30/2014 2:15:00 AM - Business Wire

Genzyme Recognizes Sixth Annual World MS Day
5/28/2014 8:00:00 AM - Business Wire

Sanofi and Lilly announce licensing agreement for Cialis® (tadalafil) OTC
5/28/2014 7:00:00 AM - PR Newswire

Genzyme’s Lemtrada Recommended for Reimbursement on NHS by the National Institute for Health and Care Excellence (NICE)
5/27/2014 7:01:00 PM - Business Wire

Rolaids® "Eat Your Words" Spelling Bee Celebrates America's Favorite, Yet Heartburn-Inducing Foods
5/22/2014 3:41:00 PM - PR Newswire

Sanofi Pasteur Announces Favorable Phase II Study Results for Investigational Clostridium difficile Vaccine at the American Society for Microbiology Meeting
5/19/2014 8:00:00 AM - PR Newswire

Jerome Bettis, Sanofi US and Allergy Foundation Launch Severe, Life-Threatening Allergies Quiz
5/13/2014 8:00:00 AM - PR Newswire

Veterans Advancing ALS/MND Wins Sanofi US Innovation Challenge: Collaborate Innovate
5/12/2014 10:28:00 AM - PR Newswire

National Survey Reveals Mothers Are Unaware of the CDC Recommendations for Prevention of Meningococcal Meningitis, a Disease That Can Potentially Kill in 24 Hours
5/12/2014 8:19:00 AM - PR Newswire

BayBio Names Henry M. Gunn High School Senior Amgen Bay Area BioGENEius Finalist
5/9/2014 6:00:00 PM - Business Wire

Genzyme and Isis Receive Corporate Award from the National Organization for Rare Disorders (NORD) for the Development of KYNAMRO®
5/8/2014 9:00:00 AM - Business Wire